{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:49:38Z","timestamp":1787849378062,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The main purpose of this study was to investigate the effects of 12\u00a0months of rhPTH (1\u201384) (Natpar<jats:sup>\u00ae<\/jats:sup>) treatment in a cohort of patients selected according to the indications of hypoparathyroidism guidelines. The use of recombinant human PTH (1\u201384) [rhPTH (1\u201384)] is approved as hormonal replacement therapy in patients with hypoparathyroidism not adequately controlled with conventional therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>It is a multicenter, observational, retro-prospective, open label study. Eleven Italian Endocrinological centers, members of Hypoparathyroidism Working Group of the Italian Society of Endocrinology (HypoparaNET) were involved. Main outcome measures were serum and urinary calcium and phosphate concentration, calcium-phosphate product, renal function, oral calcium and vitamin D doses, and clinical manifestations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fourteen adult subjects, affected by chronic hypoparathyroidism, were treated with rhPTH (1\u201384) for 12\u00a0months. At 12\u00a0months of rhPTH (1\u201384) treatment, 61.5% of patients discontinued calcium supplement and 69.2% calcitriol. Mean albumin-adjusted total serum calcium levels quickly normalized after initiation of rhPTH (1\u201384) treatment compared to baseline (<jats:italic>p<\/jats:italic>\u2009=\u20090.009), remaining in the normal range until 12\u00a0months. Rare hypo-hypercalcemia episodes were reported. Renal function was maintained normal and no renal complications were reported. Serum and urinary phosphate and urinary calcium were maintained in the normal range. Mean phosphatemia levels linearly decreased from 3\u00a0months up to 12\u00a0months compared to baseline (<jats:italic>p<\/jats:italic>\u2009=\u20090.014). No severe adverse events were described.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Biochemical and clinical results confirm the efficacy and safety of rhPTH (1\u201384) therapy, which represents an important option for hypoparathyroid patients unresponsive to conventional therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-022-01800-y","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T15:03:33Z","timestamp":1650726213000},"page":"1653-1662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1\u201384) treatment"],"prefix":"10.1007","volume":"45","author":[{"given":"G.","family":"Marcucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Beccuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Carosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cetani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cianferotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Di Somma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Duradoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Elefante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ghizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Lania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lavezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Madeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marcocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Parri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pigliaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Santonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"M. L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,23]]},"reference":[{"key":"1800_CR1","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1210\/jc.2015-3908","volume":"101","author":"BL Clarke","year":"2016","unstructured":"Clarke BL, Brown EM, Collins MT et al (2016) Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab 101:2284\u20132299","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR2","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.483","volume":"26","author":"JP Bilezikian","year":"2011","unstructured":"Bilezikian JP, Khan A, Potts Jr JT, Brandi ML, Clarke BL, Shoback D, J\u00fcppner H, D\u2019Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J (2011) Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 26:2317\u20132337. https:\/\/doi.org\/10.1002\/jbmr.483","journal-title":"J Bone Miner Res"},{"key":"1800_CR3","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-18-0609","volume":"180","author":"AA Khan","year":"2019","unstructured":"Khan AA, Koch CA, Van Uum S, Baillargeon JP, Bollerslev J, Brandi ML, Marcocci C, Rejnmark L, Rizzoli R, Shrayyef MZ, Thakker R, Yildiz BO, Clarke B (2019) Standards of care for hypoparathyroidism in adults: a canadian and international consensus. Eur J Endocrinol 180:P1\u2013P22. https:\/\/doi.org\/10.1530\/EJE-18-0609","journal-title":"Eur J Endocrinol"},{"key":"1800_CR4","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT Jr (2016) Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab 101:2273\u20132283. https:\/\/doi.org\/10.1210\/jc.2015-3907","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR5","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1210\/jc.2012-1808","volume":"97","author":"DM Mitchell","year":"2012","unstructured":"Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA, Mannstadt M (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97:4507\u20134514. https:\/\/doi.org\/10.1210\/jc.2012-1808 (Epub 2012 Oct 5)","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","volume":"276","author":"KK Winer","year":"1996","unstructured":"Winer KK, Yanovski JA, Cutler GB Jr (1996) Synthetic human parathyroid hormone 1\u201334 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 276:631\u2013636","journal-title":"JAMA"},{"key":"1800_CR7","first-page":"3480","volume":"83","author":"KK Winer","year":"1998","unstructured":"Winer KK, Yanovski JA, Sarani B, Cutler GB Jr (1998) A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1\u201334 in treatment of hypoparathyroidism. J Clin Endocrinol Metab 83:3480\u20133486","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR8","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1210\/jc.2002-021736","volume":"88","author":"KK Winer","year":"2003","unstructured":"Winer KK, Ko CW, Reynolds JC et al (2003) Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1\u201334) versus calcitriol and calcium. J Clin Endocrinol Metab 88:4214\u20134220","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR9","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1210\/jc.2009-2464","volume":"95","author":"KK Winer","year":"2010","unstructured":"Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr (2010) Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1\u201334 versus calcitriol and calcium. J Clin Endocrinol Metab 95:2680\u20132688","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR10","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1210\/jc.2007-2552","volume":"93","author":"KK Winer","year":"2008","unstructured":"Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr (2008) Effects of once versus twice-daily parathyroid hormone 1\u201334 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab 93:3389\u20133395","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR11","unstructured":"https:\/\/www.gazzettaufficiale.it\/eli\/id\/2017\/08\/17\/17A05702\/sg"},{"key":"1800_CR12","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1210\/jc.2015-1855","volume":"100","author":"A Santonati","year":"2015","unstructured":"Santonati A, Palermo A, Maddaloni E et al (2015) Hypoparathyroidism AME group. PTH(1\u201334) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab 100:3590\u20133597","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1210\/jc.2017-01555","volume":"103","author":"A Palermo","year":"2018","unstructured":"Palermo A, Santonati A, Tabacco G et al (2018) PTH (1\u201334) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab 103:271\u2013280","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12020-020-02577-x","volume":"72","author":"G Marcucci","year":"2021","unstructured":"Marcucci G, Masi L, Cianferotti L, Giusti F, Fossi C, Parri S, Gronchi G, Brandi ML (2021) Chronic hypoparathyroidism and treatment with teriparatide. Endocrine 72:249\u2013259. https:\/\/doi.org\/10.1007\/s12020-020-02577-x","journal-title":"Endocrine"},{"key":"1800_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"Mannstadt M et al (2013) Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1:275\u2013283. https:\/\/doi.org\/10.1016\/S2213-8587(13)70106-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1800_CR16","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1080\/14712598.2016.1238455","volume":"16","author":"G Marcucci","year":"2016","unstructured":"Marcucci G, Della Pepa G, Brandi ML (2016) Natpara for the treatment of hypoparathyroidism. Expert Opin Biol Ther 16:1417\u20131424. https:\/\/doi.org\/10.1080\/14712598.2016.1238455","journal-title":"Expert Opin Biol Ther"},{"key":"1800_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000491047","volume":"51","author":"G Marcucci","year":"2019","unstructured":"Marcucci G, Brandi ML (2019) A new era for chronic management of hypoparathyroidism: parathyroid hormone peptides. Front Horm Res 51:165\u2013171. https:\/\/doi.org\/10.1159\/000491047","journal-title":"Front Horm Res"},{"key":"1800_CR18","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","volume":"173","author":"B Jens","year":"2015","unstructured":"Jens B, Lars R, Claudio M, Dolores MS, Antonio SS, van Wim B, Olaf MD, European Society of Endocrinology (2015) European society of endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173:G1-20. https:\/\/doi.org\/10.1530\/EJE-15-0628","journal-title":"Eur J Endocrinol"},{"key":"1800_CR19","unstructured":"Shire-NPS Pharmaceuticals, Inc. Natpara (parathyroid hormone). Full prescribing information. Lexington, MA: Shire-NPS Pharmaceuticals, Inc.; 2016.; European Medicines Agency. Natpar (parathyroid hormone) EMA summary of product characteristics. 2017. http:\/\/www.ema.europa. eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/ human\/003861\/WC500226450.pdf"},{"key":"1800_CR20","unstructured":"Natpara [package insert]. Bedminster, NJ; NPS Pharmaceuticals, Inc; 2015"},{"key":"1800_CR21","unstructured":"https:\/\/www.ema.europa.eu\/documents\/product-information\/natpar-epar-product-information-en.pdf"},{"key":"1800_CR22","unstructured":"https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170424137423\/anx_137423_it.pdf"},{"key":"1800_CR23","unstructured":"https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2020-05-26&atto.codiceRedazionale=20A02743&elenco30giorni=false"},{"key":"1800_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00223-018-0411-7","volume":"103","author":"G Marcucci","year":"2018","unstructured":"Marcucci G, Cianferotti L, Parri S, Altieri P, Arvat E et al (2018) HypoparaNet: a database of chronic hypoparathyroidism based on expert medical-surgical centers in Italy. Calcif Tissue Int 103:151\u2013163. https:\/\/doi.org\/10.1007\/s00223-018-0411-7","journal-title":"Calcif Tissue Int"},{"key":"1800_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1472-6890-8-12","volume":"8","author":"MT James","year":"2008","unstructured":"James MT, Zhang J, Lyon AW, Hemmelgarn BR (2008) Derivation and internal validation of an equation for albumin-adjusted calcium. BMC Clin Pathol 8:12","journal-title":"BMC Clin Pathol"},{"key":"1800_CR26","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40618-020-01442-y","volume":"44","author":"NAT Hamdy","year":"2021","unstructured":"Hamdy NAT, Decallonne B, Evenepoel P, Gruson D, van Vlokhoven-Verhaegh L (2021) Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey. J Endocrinol Invest 44:1437\u20131446. https:\/\/doi.org\/10.1007\/s40618-020-01442-y","journal-title":"J Endocrinol Invest"},{"key":"1800_CR27","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40618-018-0857-5","volume":"41","author":"A Meola","year":"2018","unstructured":"Meola A, Vignali E, Matrone A, Cetani F, Marcocci C (2018) Efficacy and safety of long-term management of patients with chronic post- surgical hypoparathyroidism. J Endocrinol Invest 41:1221\u20131226. https:\/\/doi.org\/10.1007\/s40618-018-0857-5","journal-title":"J Endocrinol Invest"},{"key":"1800_CR28","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jbmr.1979","volume":"28","author":"L Underbjerg","year":"2013","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28:2277\u20132285. https:\/\/doi.org\/10.1002\/jbmr.1979","journal-title":"J Bone Miner Res"},{"key":"1800_CR29","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/jbmr.2501","volume":"30","author":"L Underbjerg","year":"2015","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res 30:1738\u20131744. https:\/\/doi.org\/10.1002\/jbmr.2501","journal-title":"J Bone Miner Res"},{"key":"1800_CR30","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1210\/jc.2013-1239","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, McMahon DJ, Irani D, Tulley A, Sliney J, Bilezikian JP (2013) The effect of PTH (1\u201384) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98:2356\u20132361. https:\/\/doi.org\/10.1210\/jc.2013-1239","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR31","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","volume":"25","author":"T Sikjaer","year":"2014","unstructured":"Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L (2014) Effects of PTH(1\u201384) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporosis Int 25:1717. https:\/\/doi.org\/10.1007\/s00198-014-2677-6","journal-title":"Osteoporosis Int"},{"key":"1800_CR32","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","volume":"101","author":"MC Astor","year":"2016","unstructured":"Astor MC, L\u00f8v\u00e5s K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB et al (2016) Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab 101:3045\u20133053. https:\/\/doi.org\/10.1210\/jc.2016-1477","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1210\/jc.2017-01471","volume":"103","author":"TJ Vokes","year":"2018","unstructured":"Vokes TJ, Mannstadt M, Levine MA, Clarke BL, Lakatos P, Chen K, Piccolo R, Krasner A, Shoback DM, Bilezikian JP (2018) Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J Clin Endocrinol Metab 103:722\u2013731. https:\/\/doi.org\/10.1210\/jc.2017-01471","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4158\/EP15936.OR","volume":"22","author":"P Lakatos","year":"2016","unstructured":"Lakatos P, Bajnok L, Lagast H, Valkusz Z (2016) An open-label extension study of parathyroid hormone rhpth(1\u201384) in adults with hypoparathyroidism. Endocr Pract 22:523\u2013532. https:\/\/doi.org\/10.4158\/EP15936.OR","journal-title":"Endocr Pract"},{"issue":"104","key":"1800_CR35","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1210\/jc.2019-01010","volume":"1","author":"M Mannstadt","year":"2019","unstructured":"Mannstadt M, Clarke BL et al (2019) Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism. J Clin Endocrinol Metab 1(104):5136\u20135147. https:\/\/doi.org\/10.1210\/jc.2019-01010","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR36","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/jbmr.4005","volume":"35","author":"NE Cusano","year":"2020","unstructured":"Cusano NE, Rubin MR, Williams JM, Agarwal S, Tabacco G, Tay D, Majeed R, Omeragic B, Bilezikian JP (2020) Changes in skeletal microstructure through four continuous years of rhPTH(1\u201384) therapy in hypoparathyroidism. J Bone Miner Res 35:1274\u20131281. https:\/\/doi.org\/10.1002\/jbmr.4005","journal-title":"J Bone Miner Res"},{"issue":"104","key":"1800_CR37","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1210\/jc.2019-00893","volume":"1","author":"YD Tay","year":"2019","unstructured":"Tay YD, Tabacco G, Cusano NE, Williams J, Omeragic B, Majeed R, Gomez Almonte M, Bilezikian JP, Rubin MR (2019) Therapy of hypoparathyroidism with rhPTH(1\u201384): a prospective, 8-year investigation of efficacy and safety. J Clin Endocrinol Metab 1(104):5601\u20135610. https:\/\/doi.org\/10.1210\/jc.2019-00893","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR38","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1210\/jc.2015-4135","volume":"101","author":"MR Rubin","year":"2016","unstructured":"Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, Cremers S, Dworakowski E, Bilezikian JP (2016) Therapy of hypoparathyroidism with PTH(1\u201384): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab 101:2742\u20132750. https:\/\/doi.org\/10.1210\/jc.2015-4135","journal-title":"J Clin Endocrinol Metab"},{"key":"1800_CR39","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/jbmr.470","volume":"26","author":"T Sikjaer","year":"2011","unstructured":"Sikjaer T et al (2011) The effect of adding PTH(1\u201384) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res 26:2358\u20132370","journal-title":"J Bone Miner Res"},{"key":"1800_CR40","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s12020-019-02105-6","volume":"66","author":"AM Formenti","year":"2019","unstructured":"Formenti AM, Tecilazich F, Frara S et al (2019) Body mass index predicts resistance to active vitamin D in patients with hypoparathyroidism. Endocrine 66:699\u2013700","journal-title":"Endocrine"},{"key":"1800_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12020-016-1141-0","volume":"55","author":"BL Clarke","year":"2017","unstructured":"Clarke BL, Vokes TJ, Bilezikian JP, Shoback DM, Lagast H, Mannstadt M (2017) Effects of parathyroid hormone rhPTH (1\u201384) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine 55:273\u2013282. https:\/\/doi.org\/10.1007\/s12020-016-1141-0","journal-title":"Endocrine"},{"key":"1800_CR42","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01922440"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01800-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01800-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01800-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T12:07:13Z","timestamp":1659960433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01800-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,23]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["1800"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01800-y","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,23]]},"assertion":[{"value":"5 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.M.L.: has received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB; has received grants from and\/or has been speaker for: Abiogen, Alexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, UCB; has been consultant for: Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB; C.A.M.: has been consultant for Analysis Group Inc (USA), Ipsen S.p.A., IQVIA RDS Switzerland, Medpace Clinical Research (USA), Novartis Farma S.p.A., Novartis Pharma Services AG (Dubai), Novo Nordisk S.p.A., Ipsen Korea, Pfizer Italia S.r.l; C.L.: received lecture fees from Abiogen Pharma, Sandoz and Metagenics and previously consulted for UCB Pharma, is a member of the Editorial Board of the Journal of Endocrinological Investigation; M.C.: has participated as advisory board: Abiogen Pharma, received grant support from: Shire\/Takeda; has participated in research trials: Ascendis Pharma, Horizon Pharma; M.G.: has previously consulted for Shire\/Takeda, Recordati, Novartis, Pfizer, received lecture fees from Recordati; C.F.: is a member of the Editorial Board of the Journal of Endocrinological Investigation. Other authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board of University Hospital Careggi of Florence, Italy (number: 10641_oss; 16 May 2017). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was approved by our local ethical committee and informed consent was obtained.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}